Lyme disease is contagious and induced by the bacteria Borrelia burgdorferi, or B. burgdorferi. It is transferred to humans by a sting from an infected black-legged or deer tick. The tick becomes contaminated after feeding on infected deer, birds, or rats. Some of the common symptoms include fever, headache, fatigue, and a distinctive skin rash called erythema migrans. The disease can further spread to joints, the heart, and the neurotic system if not treated in time. Based on symptoms, the Lyme disease is mostly treated using doxycycline, amoxicillin, or cefuroxime, which are first-line medications in grown-ups and children, while cefuroxime and amoxicillin are primarily used to treat women who are nursing or breastfeeding. Moreover, intravenous (IV) antibiotics can be used for some forms of the Lyme disease. This includes cardiac or central nervous system involvement. If any improvement is seen, many healthcare providers typically switch to an oral regimen. The primary stage of the Lyme disease can be usually treated in 14-28 days. However, the late-stage symptoms may take up to 28 days if treated with antibiotics. Medicinal developments are likely to boost the global Lyme disease treatment market during the forecast period.
Lyme disease is usually diagnosed using Borrelia antibiotics in the blood, or the cerebrospinal fluid to recognize signs and symptoms of the central nervous system disease. Medical experts suggest treatment and oral medications to ease the pain. In some cases, different tick-borne diseases, syphilis, or lupus can display similar symptoms as Lyme disease. Thus, the treatment is given after carefully diagnosing the symptoms using a couple of ways. The U.S. reports around half a million cases every year. The increasing frequency of the Lyme disease, and rising investments from government organizations and large corporates for developing advanced treatment are some of the primary factors contributing to the growth of the global Lyme disease treatment market during the forecast period.
The coronavirus pandemic has switched all the medical and healthcare sectors toward the diagnosis and treatment of COVID-19 patients. This has impacted other areas of health and treatment, including the Lyme disease treatment market. A patient’s concern for the contamination has reduced outpatient visits with healthcare providers. Indicative patients may be deemed to have COVID-19 until negative test results are collected, signifying that evaluations for other treatments will be delayed, possibly leading to unfavorable outcomes. Individuals with Lyme disease symptoms were asked to suspend their tests as the coronavirus spread began to take over the world. People were advised to be in quarantine, as evaluation for other causes of the patient’s symptoms other than the COVID-19 virus was often delayed, risking delayed treatments and complications. Moreover, as the Lyme disease and the COVID-19 virus often start with non-specific flu-like symptoms with fever, headache, and general achiness and fatigue, it made patients and medical experts more concerned about both infections in individuals. Thus, patients were suggested to treat with the available oral medications helping to diagnose other diseases.
The impact of COVID-19 on Lyme disease treatment market has been unexpected, far-reaching, and diverse. Across several nations, Lyme disease treatment has made tremendous developments to assure patients continue to receive critical treatment, and new safety standards are attained to protect medical staff and clients. Lyme disease experts have implemented a variety of operational procedures and careful measures to maintain adequate treatment, while restricting the spread of the coronavirus and prioritizing safety. Furthermore, delays in the treatment of Lyme disease can possibly result in bacterial diffusion and reflection of distant organ systems, most importantly, the neurologic, cardiac, and musculoskeletal systems. Nevertheless, the world is starting to open up as the rate of vaccine production and distribution has increased. Post COVID-19, however, there is expected to be a significant increase in the treatment of Lyme disease, as the number of people scared to move out can safely visit the medical care facility. Thus is likely to drive the Lyme disease treatment market in the upcoming future.
Medical organizations are funding placebo-controlled clinical trials to study more about the effectiveness of the prolonged antibiotic therapy for the Lyme disease treatment. The advancement in research in the Lyme disease treatment market of a new cytokine-based immunoassay for Lyme disease can provide an earlier and more rapid examination of the disease, if successful. Using advanced technologies, several researchers are examining a new, rapid point-of-care Lyme treatment. Further studies are expected to contribute to new ways for identifying the Lyme disease, earlier-stage examination, accurate staging of disease, or indications of successful treatment. The improvements in the Lyme disease treatment portfolio by various key players operating in the Lyme disease treatment market have embraced the approval by innovating simple and effective Lyme disease treatments. The National Institutes of Health (NIH) has invested in multiple types of research on the treatment of the Lyme disease that exhibit most people recover within weeks of finishing a course of oral medicines when treated soon after symptom origin. In very few cases, symptoms such as fatigue and muscle aches can last for more than six months. This condition is known as post-treatment Lyme disease syndrome (PTLDS), although it is also seldom called chronic Lyme disease.
The Lyme disease in canines has been inscribed in various geographical regions, especially in the U.S., but certain areas around the world are much more likely to harbor bacteria-carrying ticks than others. The symptoms of the Lyme disease vary in animals. Many animals can have the Lyme disease and exhibit no symptoms. In dogs, the most basic symptoms include fever, loss of appetite, aching or swelled joints, lameness, swollen lymph joints, and laziness. If the Lyme disease is left untreated, it can lead to severe harm to the kidneys, nervous system, and heart. Lyme disease affecting the organs is the second most basic syndrome in dogs and is usually fatal. Facial insensibility and seizure disorders have been reported from the disease affecting the nervous system. The growing human affection toward dogs is boosting the growth of the global market. The global Lyme disease treatment market is projected to reach US$ 3 Bn by 2031, at a CAGR of ~6% from 2021 to 2031.
Analysts’ Viewpoint
The rise in prevalence of the Lyme disease in humans and animals demands effective treatment. The increasing awareness regarding tick-borne diseases and veterinary care contributes to the growth of the Lyme disease treatment market. Growing investments in R&D activities are expected to result in more effective treatment for the Lyme disease. However, the rising number of generic products for the Lyme disease treatment is hindering market growth. Nevertheless, rapid development in studies and diagnosis of the Lyme disease is anticipated to innovate new ways to treat the disease. Moreover, rising government investments in spreading awareness for animal care and harms of the Lyme disease are anticipated to drive the global Lyme disease treatment market during the forecast period.
Lyme Disease Treatment Market – Segmentation
| Treatment Type |
|
| Type of Bacteria |
|
| Route of Administration |
|
| Application |
|
| Distribution Channel |
|
| Region |
|
Lyme disease treatment market is projected to reach US$ 3 Bn by 2031
Lyme disease treatment market to expand at a CAGR of ~6% from 2021 to 2031
Lyme disease treatment market is driven by increase in pet ownership, surge in awareness & adoption of veterinary care, and rise in healthcare expenditure on animals
North America is expected to account for a significant share of the global Lyme disease treatment market during the forecast period
Key players operating in the global Lyme disease treatment market include GlaxoSmithKline plc, Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Almirall, LLC, Mayne Pharma
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lyme Disease Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Market Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lyme Disease Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.2. Key Industry Events (mergers and acquisitions, new product development, technological advancements, etc.)
5.3. Lyme Disease Treatment Overview
5.4. Severity of Diseases (Lyme Arthritis, Carditis and Neurological Symptoms)
5.5. Epidemiology of Lyme Disease Region/Country
5.6. Tick Geography Analysis by Respective Countries
6. Global Lyme Disease Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2031
6.3.1. Medication
6.3.1.1. Antibiotics
6.3.1.1.1. Cephalosporin
6.3.1.1.2. Tetracycline
6.3.1.1.3. Macrolides
6.3.1.1.4. Others
6.3.1.2. NSAID
6.3.1.3. Others
6.3.2. Tick Removal
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Lyme Disease Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Injectable
7.3.3. Topical
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Lyme Disease Treatment Market Analysis and Forecast, by Type of Bacteria
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Type of Bacteria, 2017–2031
8.3.1. Borrelia burgdorferi
8.3.2. Borrelia mayonii
8.3.3. Borrelia afzelii
8.3.4. Borrelia garinii
8.3.5. Others
8.4. Market Attractiveness Analysis, by Type of Bacteria
9. Global Lyme Disease Treatment Market Analysis and Forecast, by Application
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Application, 2017–2031
9.3.1. Humans
9.3.2. Animals
9.4. Market Attractiveness Analysis, by Application
10. Global Lyme Disease Treatment Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Lyme Disease Treatment Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Country/Region
12. North America Lyme Disease Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2031
12.2.1. Medication
12.2.1.1. Antibiotics
12.2.1.1.1. Cephalosporin
12.2.1.1.2. Tetracycline
12.2.1.1.3. Macrolides
12.2.1.1.4. Others
12.2.1.2. NSAID
12.2.1.3. Others
12.2.2. Tick Removal
12.3. Market Value Forecast, by Route of Administration, 2017–2031
12.3.1. Oral
12.3.2. Injectable
12.3.3. Topical
12.4. Market Value Forecast, by Type of Bacteria, 2017–2031
12.4.1. Borrelia burgdorferi
12.4.2. Borrelia mayonii
12.4.3. Borrelia afzelii
12.4.4. Borrelia garinii
12.4.5. Others
12.5. Market Value Forecast, by Application, 2017–2031
12.5.1. Humans
12.5.2. Animals
12.6. Market Value Forecast, by Distribution Channel, 2017–2031
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Value Forecast, by Country, 2017–2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Treatment Type
12.8.2. By Route of Administration
12.8.3. By Type of Bacteria
12.8.4. By Application
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Lyme Disease Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017–2031
13.2.1. Medication
13.2.1.1. Antibiotics
13.2.1.1.1. Cephalosporin
13.2.1.1.2. Tetracycline
13.2.1.1.3. Macrolides
13.2.1.1.4. Others
13.2.1.2. NSAID
13.2.1.3. Others
13.2.2. Tick Removal
13.3. Market Value Forecast, by Route of Administration, 2017–2031
13.3.1. Oral
13.3.2. Injectable
13.3.3. Topical
13.4. Market Value Forecast, by Type of Bacteria, 2017–2031
13.4.1. Borrelia burgdorferi
13.4.2. Borrelia mayonii
13.4.3. Borrelia afzelii
13.4.4. Borrelia garinii
13.4.5. Others
13.5. Market Value Forecast, by Application, 2017–2031
13.5.1. Humans
13.5.2. Animals
13.6. Market Value Forecast, by Distribution Channel, 2017–2031
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Value Forecast, by Country/Sub-region, 2017–2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Treatment Type
13.8.2. By Route of Administration
13.8.3. By Type of Bacteria
13.8.4. By Application
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Lyme Disease Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Type, 2017–2031
14.2.1. Medication
14.2.1.1. Antibiotics
14.2.1.1.1. Cephalosporin
14.2.1.1.2. Tetracycline
14.2.1.1.3. Macrolides
14.2.1.1.4. Others
14.2.1.2. NSAID
14.2.1.3. Others
14.2.2. Tick Removal
14.3. Market Value Forecast, by Route of Administration, 2017–2031
14.3.1. Oral
14.3.2. Injectable
14.3.3. Topical
14.4. Market Value Forecast, by Type of Bacteria, 2017–2031
14.4.1. Borrelia burgdorferi
14.4.2. Borrelia mayonii
14.4.3. Borrelia afzelii
14.4.4. Borrelia garinii
14.4.5. Others
14.5. Market Value Forecast, by Application, 2017–2031
14.5.1. Humans
14.5.2. Animals
14.6. Market Value Forecast, by Distribution Channel, 2017–2031
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Value Forecast, by Country/Sub-region, 2017–2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Treatment Type
14.8.2. By Route of Administration
14.8.3. By Type of Bacteria
14.8.4. By Application
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Lyme Disease Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment Type, 2017–2031
15.2.1. Medication
15.2.1.1. Antibiotics
15.2.1.1.1. Cephalosporin
15.2.1.1.2. Tetracycline
15.2.1.1.3. Macrolides
15.2.1.1.4. Others
15.2.1.2. NSAID
15.2.1.3. Others
15.2.2. Tick Removal
15.3. Market Value Forecast, by Route of Administration, 2017–2031
15.3.1. Oral
15.3.2. Injectable
15.3.3. Topical
15.4. Market Value Forecast, by Type of Bacteria, 2017–2031
15.4.1. Borrelia burgdorferi
15.4.2. Borrelia mayonii
15.4.3. Borrelia afzelii
15.4.4. Borrelia garinii
15.4.5. Others
15.5. Market Value Forecast, by Application, 2017–2031
15.5.1. Humans
15.5.2. Animals
15.6. Market Value Forecast, by Distribution Channel, 2017–2031
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Pharmacies
15.7. Market Value Forecast, by Country/Sub-region, 2017–2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Treatment Type
15.8.2. By Route of Administration
15.8.3. By Type of Bacteria
15.8.4. By Application
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Lyme Disease Treatment Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Treatment Type, 2017–2031
16.2.1. Medication
16.2.1.1. Antibiotics
16.2.1.1.1. Cephalosporin
16.2.1.1.2. Tetracycline
16.2.1.1.3. Macrolides
16.2.1.1.4. Others
16.2.1.2. NSAID
16.2.1.3. Others
16.2.2. Tick Removal
16.3. Market Value Forecast, by Route of Administration, 2017–2031
16.3.1. Oral
16.3.2. Injectable
16.3.3. Topical
16.4. Market Value Forecast, by Type of Bacteria, 2017–2031
16.4.1. Borrelia burgdorferi
16.4.2. Borrelia mayonii
16.4.3. Borrelia afzelii
16.4.4. Borrelia garinii
16.4.5. Others
16.5. Market Value Forecast, by Application, 2017–2031
16.5.1. Humans
16.5.2. Animals
16.6. Market Value Forecast, by Distribution Channel, 2017–2031
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Pharmacies
16.7. Market Value Forecast, by Country/Sub-region, 2017–2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Treatment Type
16.8.2. By Route of Administration
16.8.3. By Type of Bacteria
16.8.4. By Application
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (by Tier and Size of companies)
17.2. Market Share Analysis/Ranking, by Company, 2020
17.3. Company Profiles
17.3.1. GlaxoSmithKline plc
17.3.1.1. Company Description
17.3.1.2. Business Overview
17.3.1.3. Strategic Overview
17.3.1.4. SWOT Analysis
17.3.2. Pfizer, Inc.
17.3.2.1. Company Description
17.3.2.2. Business Overview
17.3.2.3. Strategic Overview
17.3.2.4. SWOT Analysis
17.3.3. Novartis AG
17.3.3.1. Company Description
17.3.3.2. Business Overview
17.3.3.3. Strategic Overview
17.3.3.4. SWOT Analysis
17.3.4. F. Hoffmann-La Roche Ltd.
17.3.4.1. Company Description
17.3.4.2. Business Overview
17.3.4.3. Strategic Overview
17.3.4.4. SWOT Analysis
17.3.5. Almirall, LLC
17.3.5.1. Company Description
17.3.5.2. Business Overview
17.3.5.3. Strategic Overview
17.3.5.4. SWOT Analysis
17.3.6. Mayne Pharma
17.3.6.1. Company Description
17.3.6.2. Business Overview
17.3.6.3. Strategic Overview
17.3.6.4. SWOT Analysis
17.3.7. Boehringer Ingelheim International GmbH
17.3.7.1. Company Description
17.3.7.2. Business Overview
17.3.7.3. Strategic Overview
17.3.7.4. SWOT Analysis
17.3.8. Galderma Laboratories, L.P.
17.3.8.1. Company Description
17.3.8.2. Business Overview
17.3.8.3. Strategic Overview
17.3.8.4. SWOT Analysis
17.3.9. Lupin Pharmaceuticals, Inc.
17.3.9.1. Company Description
17.3.9.2. Business Overview
17.3.9.3. Strategic Overview
17.3.9.4. SWOT Analysis
17.3.10. Chartwell Pharmaceuticals
17.3.10.1. Company Description
17.3.10.2. Business Overview
17.3.10.3. Strategic Overview
17.3.10.4. SWOT Analysis
17.3.11. Sun Pharmaceutical Industries Ltd.
17.3.11.1. Company Description
17.3.11.2. Business Overview
17.3.11.3. Strategic Overview
17.3.11.4. SWOT Analysis
17.3.12. Perrigo Company plc
17.3.12.1. Company Description
17.3.12.2. Business Overview
17.3.12.3. Strategic Overview
17.3.12.4. SWOT Analysis
17.3.13. Orion Corporation
17.3.13.1. Company Description
17.3.13.2. Business Overview
17.3.13.3. Strategic Overview
17.3.13.4. SWOT Analysis
17.3.14. Amneal Pharmaceuticals LLC
17.3.14.1. Company Description
17.3.14.2. Business Overview
17.3.14.3. Strategic Overview
17.3.14.4. SWOT Analysis
List of Tables
Table 01: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 02: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Medication, 2017–2031
Table 03: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 04: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 05: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Type of Bacteria, 2017–2031
Table 06: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 07: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 08: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Region/Country, 2017–2031
Table 09: North America Lyme Disease Treatment Market Revenue (US$ Mn) Forecast, by Country, 2017–2031
Table 10: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 11: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Medication, 2017–2031
Table 12: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 13: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 14: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Type of Bacteria, 2017–2031
Table 15: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 16: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 19: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Medication, 2017–2031
Table 20: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 21: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 22: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Type of Bacteria, 2017–2031
Table 23: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 25: Asia Pacific Lyme Disease Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2015–2031
Table 26: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 27: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Medication, 2017–2031
Table 28: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 29: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 30: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Type of Bacteria, 2017–2031
Table 31: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 32: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 33: Latin America Lyme Disease Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 34: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 35: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Medication, 2017–2031
Table 36: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 37: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 38: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Type of Bacteria, 2017–2031
Table 39: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 40: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 41: Middle East & Africa Lyme Disease Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 42: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 43: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Medication, 2017–2031
Table 44: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 45: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 46: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Type of Bacteria, 2017–2031
Table 47: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 48: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Lyme Disease Treatment Market Value Share, by Treatment Type, 2020
Figure 03: Global Lyme Disease Treatment Market Value Share, by Route of Administration, 2020
Figure 04: Global Lyme Disease Treatment Market Value Share, by Type of Bacteria, 2020
Figure 05: Global Lyme Disease Treatment Market Value Share, by Application, 2020
Figure 07: Global Lyme Disease Treatment Market Value Share Analysis, by Treatment Type, 2020 and 2031
Figure 08: Global Lyme Disease Treatment Market Attractiveness Analysis, by Treatment Type, 2021–2031
Figure 09: Global Lyme Disease Treatment Market Value Share Analysis, by Medication, 2020 and 2031
Figure 10: Global Lyme Disease Treatment Market Attractiveness Analysis, by Medication, 2021–2031
Figure 11: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Medication, 2017–2031
Figure 12: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Tick Removal, 2017–2031
Figure 13: Global Lyme Disease Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 14: Global Lyme Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 15: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Oral, 2017–2031
Figure 16: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Injectable, 2017–2031
Figure 17: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Topical, 2017–2031
Figure 18: Global Lyme Disease Treatment Market Value Share Analysis, by Type of Bacteria, 2020 and 2031
Figure 19: Global Lyme Disease Treatment Market Attractiveness Analysis, by Type of Bacteria, 2021–2031
Figure 20: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Borrelia burgdorferi, 2017–2031
Figure 21: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Borrelia mayonii, 2017–2031
Figure 22: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Borrelia afzelii, 2017–2031
Figure 23: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Borrelia garinii, 2017–2031
Figure 24: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Others, 2017–2031
Figure 25: Global Lyme Disease Treatment Market Value Share Analysis, by Application, 2020 and 2031
Figure 26: Global Lyme Disease Treatment Market Attractiveness Analysis, by Application, 2021–2031
Figure 27: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Humans, 2017–2031
Figure 28: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Animals, 2017–2031
Figure 29: Global Lyme Disease Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 30: Global Lyme Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 31: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031
Figure 32: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 33: Global Lyme Disease Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031
Figure 34: Global Lyme Disease Treatment Market Value Share Analysis, by Region/Country, 2020 and 2031
Figure 35: Global Lyme Disease Treatment Market Attractiveness Analysis, by Region/Country, 2021–2031
Figure 36: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 37: North America Lyme Disease Treatment Market Value Share (%), by Country, 2020 and 2031
Figure 38: North America Lyme Disease Treatment Market Attractiveness Analysis, by Country, 2021–2031
Figure 39: North America Lyme Disease Treatment Market Value Share (%), by Treatment Type, 2020 and 2031
Figure 40: North America Lyme Disease Treatment Market Attractiveness Analysis, by Treatment Type, 2021–2031
Figure 41: North America Lyme Disease Treatment Market Value Share (%), by Route of Administration, 2020 and 2031
Figure 42: North America Lyme Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 43: North America Lyme Disease Treatment Market Value Share (%), by Type of Bacteria, 2020 and 2031
Figure 44: North America Lyme Disease Treatment Market Attractiveness Analysis, by Type of Bacteria, 2021–2031
Figure 45: North America Lyme Disease Treatment Market Value Share (%), by Application, 2020 and 2031
Figure 46: North America Lyme Disease Treatment Market Attractiveness Analysis, by Application, 2021–2031
Figure 47: North America Lyme Disease Treatment Market Value Share (%), by Distribution Channel, 2020 and 2031
Figure 48: North America Lyme Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 49: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 50: Europe Lyme Disease Treatment Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 51: Europe Lyme Disease Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 52: Europe Lyme Disease Treatment Market Value Share (%), by Treatment Type, 2020 and 2031
Figure 53: Europe Lyme Disease Treatment Market Attractiveness Analysis, by Treatment Type, 2021–2031
Figure 54: Europe Lyme Disease Treatment Market Value Share (%), by Route of Administration, 2020 and 2031
Figure 55: Europe Lyme Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 56: Europe Lyme Disease Treatment Market Value Share (%), by Type of Bacteria, 2020 and 2031
Figure 57: Europe Lyme Disease Treatment Market Attractiveness Analysis, by Type of Bacteria, 2021–2031
Figure 58: Europe Lyme Disease Treatment Market Value Share (%), by Application, 2020 and 2031
Figure 59: Europe Lyme Disease Treatment Market Attractiveness Analysis, by Application, 2021–2031
Figure 60: Europe Lyme Disease Treatment Market Value Share (%), by Distribution Channel, 2020 and 2031
Figure 61: Europe Lyme Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 62: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 63: Asia Pacific Exosome Technologies Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 64: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 65: Asia Pacific Lyme Disease Treatment Market Value Share (%), by Treatment Type, 2020 and 2031
Figure 66: Asia Pacific Lyme Disease Treatment Market Attractiveness Analysis, by Treatment Type, 2021–2031
Figure 67: Asia Pacific Lyme Disease Treatment Market Value Share (%), by Route of Administration, 2020 and 2031
Figure 68: Asia Pacific Lyme Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 69: Asia Pacific Lyme Disease Treatment Market Value Share (%), by Type of Bacteria, 2020 and 2031
Figure 70: Asia Pacific Lyme Disease Treatment Market Attractiveness Analysis, by Type of Bacteria, 2021–2031
Figure 71: Asia Pacific Lyme Disease Treatment Market Value Share (%), by Application, 2020 and 2031
Figure 72: Asia Pacific Lyme Disease Treatment Market Attractiveness Analysis, by Application, 2021–2031
Figure 73: Asia Pacific Lyme Disease Treatment Market Value Share (%), by Distribution Channel, 2020 and 2031
Figure 74: Asia Pacific Lyme Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 75: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 76: Latin America Lyme Disease Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 77: Latin America Lyme Disease Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 78: Latin America Lyme Disease Treatment Market Value Share (%), by Treatment Type, 2020 and 2031
Figure 79: Latin America Lyme Disease Treatment Market Attractiveness Analysis, by Treatment Type, 2021–2031
Figure 80: Latin America Lyme Disease Treatment Market Value Share (%), by Route of Administration, 2020 and 2031
Figure 81: Latin America Lyme Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 82: Latin America Lyme Disease Treatment Market Value Share (%), by Type of Bacteria, 2020 and 2031
Figure 83: Latin America Lyme Disease Treatment Market Attractiveness Analysis, by Type of Bacteria, 2021–2031
Figure 84: Latin America Lyme Disease Treatment Market Value Share (%), by Application, 2020 and 2031
Figure 85: Latin America Lyme Disease Treatment Market Attractiveness Analysis, by Application, 2021–2031
Figure 86: Latin America Lyme Disease Treatment Market Value Share (%), by Distribution Channel, 2020 and 2031
Figure 87: Latin America Lyme Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 88: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 89: Middle East & Africa Lyme Disease Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 90: Middle East & Africa Lyme Disease Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 91: Middle East & Africa Lyme Disease Treatment Market Value Share (%), by Treatment Type, 2020 and 2031
Figure 92: Middle East & Africa Lyme Disease Treatment Market Attractiveness Analysis, by Treatment Type, 2021–2031
Figure 93: Middle East & Africa Lyme Disease Treatment Market Value Share (%), by Route of Administration, 2020 and 2031
Figure 94: Middle East & Africa Lyme Disease Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 95: Middle East & Africa Lyme Disease Treatment Market Value Share (%), by Type of Bacteria, 2020 and 2031
Figure 96: Middle East & Africa Lyme Disease Treatment Market Attractiveness Analysis, by Type of Bacteria, 2021–2031
Figure 97: Middle East & Africa Lyme Disease Treatment Market Value Share (%), by Application, 2020 and 2031
Figure 98: Middle East & Africa Lyme Disease Treatment Market Attractiveness Analysis, by Application, 2021–2031
Figure 99: Middle East & Africa Lyme Disease Treatment Market Value Share (%), by Distribution Channel, 2020 and 2031
Figure 100: Middle East & Africa Lyme Disease Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Lyme Disease Treatment Market
